PORTFOLIO COMPANIES




Portfolio Companies | Former Portfolio Companies

ExSAR Corporation, utilizes its Hydrogen/Deuterium Exchange Mass Spectrometry platform technology (H/D-Ex) to screen lead compounds for the ability to prevent protein misfolding and restore protein function. ExSAR provides H/D-Ex technology as a service to clients looking to have antigen antibody epitope mapping performed to help with their early stage lead selection, characterize proteins, identify ligand binding sites and determine comparability between biosimilars and their originator drugs as well as batch to batch studies. ExSAR continues to be a leader in the field of H/D-Exchange, and continually seeks to improve its technology while providing superior customized services to its clients. ExSAR is currently the only company offering H/D-Exchange Mass Spectrometry services to third parties. (www.exsar.com)


 
 

Pharmos acquired Vela and their drug for IBS-d (Irritable Bowel Syndrome). This drug is in a Phase II trial. (www.pharmoscorp.com)

Pharmos finished the IIa and IIb trial, and the results are documented on the Pharmos website. In addition the company has several early stage compounds that it is attempting to out license, including S tofisopam potentially for gout.

 

 
 
RETROTOPE

RETROTOPE is a privately held company focused on the development of ways of controlling metabolic processes associated with the oxidative stress conditions. Areas of interest include aging and age-related disease. RETROTOPE uses isotope effect to slow down damaging pathways. The company has several discovery and development programmes that involve major classes of biopolymers. (www.retrotrope.com)

 

 

back to top

 

Former Portfolio Companies

 

PharmaStem (formerly Biocyte) is focused on sourcing stem cells from umbilical cord blood as an an important alternative to cells from bone marrow and peripheral blood for treatment of cancers, immune-specific diseases and gene therapy.

 
 
 
Targent, Inc.

Targent Inc. focuses on the repositioning and reformulation of older cancer therapeutics and is screening a range of new compounds for novel hits. Targent was sold to Spectrum Pharmaceuticals in 2006. (www.spectrumpharm.com)

 
 
 
i-STAT

i-STAT: (STAT) Develops and manufactures pocket-sized clinical chemistry analyzers and disposables providing accurate, real-time measurements of blood analytes for point-of-care testing. IStat was sold to Abbott Laboratories. (www.i-stat.com)

 
 
 
Envirogen Envirogen (ENVG) uses unique biotechnologies for microbial degradation of toxic waste, including PCBs and TCE, hydrocarbon remediation and developing advanced biotreatment systems for the destruction of contaminants in soils, air, and waterways. Envirogen was acquired by Shaw Group. (www.shawgrp.com)
 
 
 
Sepracor Sepracor (SEPR) is a specialty pharmaceutical company focusing on intellectual properties based on the purification of isomers and their metabolites. They are marketing several of these compounds with major pharmaceutical companies. Sepracor markets a drug Lunesta for sleep directly to doctors and markets Xoponex and related allergy and asthma drugs. (www.sunovion.com) Sepracor was acquired by Dainippon Sumitomo Pharma Co., Ltd.in October, 2009.
 

 

back to top

 
 
 
home | about johnston associates inc. | our services | portfolio | contact us